Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2641 – 2660 of 3231

Recognizing and Managing Antiretroviral Treatment Failure

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/recognizing-and-managing-antiretroviral-treatment-failure

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/malaria

What's New in the Guidelines

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new

Immunizations for Preventable Diseases in Adults and Adolescents With HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/immunizations

Delavirdine (Rescriptor, DLV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-delavirdine-rescriptor

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/etravirine

Gastrointestinal Effects

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/gastrointestinal-effects

Atazanavir (Reyataz, ATV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-protease-inhibitors-atazanavir-reyataz

Nelfinavir (Viracept, NFV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-nelfinavir-viracept

Table 14. Antiretroviral Drug Use in Pregnant People With HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy | Overview

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-drug-use-pregnant-overview

Appendix B: Web-Based Resources for Treating and Preventing HIV

https://clinicalinfo.hiv.gov/guidelines/guidance-hiv-disasters/appendix-web-based-resources-treating-preventing

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/dyslipidemia

Table 4. Common Drugs Used for Treatment of Opportunistic Infections in Children With HIV: Preparations and Major Toxicities

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-4-common-drugs-used

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/tenofovir-af

Modifying Antiretroviral Regimens in Children With Sustained Virologic Suppression on Antiretroviral Therapy

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/modifying-antiretroviral-regimens-children-sustained-virologic-suppression

Abacavir (Ziagen, ABC)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nrtis-abacavir-ziagen

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/rilpivirine

Figure 1. Recommended Immunization Schedule for Children with HIV Infection Aged 0 through 18 Years; United States, 2025

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/recommended-immunizations-schedule

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/tipranavir

What’s New in the Guidelines

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new